Literature DB >> 3214464

Familial hypercholesterolemia and apolipoprotein E4.

M Eto1, K Watanabe, N Chonan, K Ishii.   

Abstract

The purpose of this study was to elucidate the relationship between two genetic factors associated with raised blood cholesterol, i.e. familial hypercholesterolemia (FH) and apolipoprotein (apo) E4. A group of 50 unrelated heterozygous FH patients aged 33-71 years were studied together with 129 normolipidemic subjects. A significantly higher frequency of apo E4 phenotypes was found in FH patients (30.0%) than in normolipidemic subjects (15.5%). FH patients were divided into two groups with and without apo E4. Plasma total cholesterol (Chol) and triglyceride (TG) levels were significantly higher, and plasma low density lipoprotein-cholesterol (LDL-Chol) level tended to be higher in FH patients with apo E4 than in those without apo E4. In addition, the prevalence of ischemic heart disease (IHD) was significantly higher in FH patients with apo E4 (73.3%) than in those without apo E4 (31.4%). No significant difference was noted in age and in the prevalence of obesity, diabetes, hypertension and smoking between the FH groups with and without apo E4. These results suggest that apo E4 is associated with higher levels of total Chol and TG and, at least in part, contributes to the predisposition to IHD in FH.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3214464     DOI: 10.1016/0021-9150(88)90072-x

Source DB:  PubMed          Journal:  Atherosclerosis        ISSN: 0021-9150            Impact factor:   5.162


  13 in total

Review 1.  Role of lipid-lowering pharmacotherapy in children.

Authors:  S Tonstad
Journal:  Paediatr Drugs       Date:  2000 Jan-Feb       Impact factor: 3.022

Review 2.  Dyslipidemia and dementia: current epidemiology, genetic evidence, and mechanisms behind the associations.

Authors:  Christiane Reitz
Journal:  J Alzheimers Dis       Date:  2012       Impact factor: 4.472

3.  Recent origin and spread of a common Lithuanian mutation, G197del LDLR, causing familial hypercholesterolemia: positive selection is not always necessary to account for disease incidence among Ashkenazi Jews.

Authors:  R Durst; R Colombo; S Shpitzen; L B Avi; Y Friedlander; R Wexler; F J Raal; D A Marais; J C Defesche; M Y Mandelshtam; M J Kotze; E Leitersdorf; V Meiner
Journal:  Am J Hum Genet       Date:  2001-04-17       Impact factor: 11.025

Review 4.  Does the oxysterol 27-hydroxycholesterol underlie Alzheimer's disease-Parkinson's disease overlap?

Authors:  Gurdeep Marwarha; Othman Ghribi
Journal:  Exp Gerontol       Date:  2014-09-28       Impact factor: 4.032

Review 5.  Dyslipidemia and the risk of Alzheimer's disease.

Authors:  Christiane Reitz
Journal:  Curr Atheroscler Rep       Date:  2013-03       Impact factor: 5.113

Review 6.  Potential mechanisms linking cholesterol to Alzheimer's disease-like pathology in rabbit brain, hippocampal organotypic slices, and skeletal muscle.

Authors:  Othman Ghribi
Journal:  J Alzheimers Dis       Date:  2008-12       Impact factor: 4.472

7.  Genetic analysis of Indian subjects with clinical features of possible type IIa hypercholesterolemia.

Authors:  Altaf A Kondkar; Kappiareth G Nair; Tester F Ashavaid
Journal:  J Clin Lab Anal       Date:  2007       Impact factor: 2.352

8.  Apolipoprotein E4 polymorphism as risk factor for coronary heart disease among Indian subjects.

Authors:  Tester F Ashavaid; Seema P Todur; Kappiareth G Nair
Journal:  Indian J Clin Biochem       Date:  2002-01

9.  Apolipoprotein E phenotype and lipoprotein(a) in familial hypercholesterolaemia: implication for lipoprotein(a) metabolism.

Authors:  G Lindahl; F Mailly; S Humphries; M Seed
Journal:  Clin Investig       Date:  1994-08

10.  Reductions in all-cause, cancer, and coronary mortality in statin-treated patients with heterozygous familial hypercholesterolaemia: a prospective registry study.

Authors:  Andrew Neil; Jackie Cooper; John Betteridge; Nigel Capps; Ian McDowell; Paul Durrington; Mary Seed; Steve E Humphries
Journal:  Eur Heart J       Date:  2008-10-07       Impact factor: 29.983

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.